331 related articles for article (PubMed ID: 22090419)
41. Conjugated linoleic acid inhibits osteoclast differentiation of RAW264.7 cells by modulating RANKL signaling.
Rahman MM; Bhattacharya A; Fernandes G
J Lipid Res; 2006 Aug; 47(8):1739-48. PubMed ID: 16702601
[TBL] [Abstract][Full Text] [Related]
42. Dehydrocostus lactone attenuates osteoclastogenesis and osteoclast-induced bone loss by modulating NF-κB signalling pathway.
Hu B; Wu F; Shi Z; He B; Zhao X; Wu H; Yan S
J Cell Mol Med; 2019 Aug; 23(8):5762-5770. PubMed ID: 31225720
[TBL] [Abstract][Full Text] [Related]
43. Leonurine hydrochloride inhibits osteoclastogenesis and prevents osteoporosis associated with estrogen deficiency by inhibiting the NF-κB and PI3K/Akt signaling pathways.
Yuan FL; Xu RS; Jiang DL; He XL; Su Q; Jin C; Li X
Bone; 2015 Jun; 75():128-37. PubMed ID: 25708053
[TBL] [Abstract][Full Text] [Related]
44. Calebin A downregulates osteoclastogenesis through suppression of RANKL signalling.
Tyagi AK; Prasad S; Majeed M; Aggarwal BB
Arch Biochem Biophys; 2016 Mar; 593():80-9. PubMed ID: 26874195
[TBL] [Abstract][Full Text] [Related]
45. Garcinol suppresses RANKL-induced osteoclastogenesis and its underlying mechanism.
Jia Y; Jiang J; Lu X; Zhang T; Zhao K; Han W; Yang W; Qian Y
J Cell Physiol; 2019 May; 234(5):7498-7509. PubMed ID: 30471112
[TBL] [Abstract][Full Text] [Related]
46. CST6 protein and peptides inhibit breast cancer bone metastasis by suppressing CTSB activity and osteoclastogenesis.
Li X; Liang Y; Lian C; Peng F; Xiao Y; He Y; Ma C; Wang Y; Zhang P; Deng Y; Su Y; Luo C; Kong X; Yang Q; Liu T; Hu G
Theranostics; 2021; 11(20):9821-9832. PubMed ID: 34815788
[No Abstract] [Full Text] [Related]
47. Neogambogic Acid Suppresses Receptor Activator of Nuclear Factor κB Ligand (RANKL)-Induced Osteoclastogenesis by Inhibiting the JNK and NF-κB Pathways in Mouse Bone Marrow-Derived Monocyte/Macrophages.
Jin G; Wang FF; Li T; Jia DD; Shen Y; Xu HC
Med Sci Monit; 2018 Apr; 24():2569-2577. PubMed ID: 29698379
[TBL] [Abstract][Full Text] [Related]
48. Stachydrine prevents LPS-induced bone loss by inhibiting osteoclastogenesis via NF-κB and Akt signalling.
Meng J; Zhou C; Zhang W; Wang W; He B; Hu B; Jiang G; Wang Y; Hong J; Li S; He J; Yan S; Yan W
J Cell Mol Med; 2019 Oct; 23(10):6730-6743. PubMed ID: 31328430
[TBL] [Abstract][Full Text] [Related]
49. Shikonin mitigates ovariectomy-induced bone loss and RANKL-induced osteoclastogenesis via TRAF6-mediated signaling pathways.
Chen K; Yan Z; Wang Y; Yang Y; Cai M; Huang C; Li B; Yang M; Zhou X; Wei X; Yang C; Chen Z; Zhai X; Li M
Biomed Pharmacother; 2020 Jun; 126():110067. PubMed ID: 32272431
[TBL] [Abstract][Full Text] [Related]
50. β-Carotene suppresses osteoclastogenesis and bone resorption by suppressing NF-κB signaling pathway.
Wang F; Wang N; Gao Y; Zhou Z; Liu W; Pan C; Yin P; Yu X; Tang M
Life Sci; 2017 Apr; 174():15-20. PubMed ID: 28263804
[TBL] [Abstract][Full Text] [Related]
51. 15-deoxy-δ12,14-prostaglandin j2 inhibits osteolytic breast cancer bone metastasis and estrogen deficiency-induced bone loss.
Kim KR; Kim HJ; Lee SK; Ma GT; Park KK; Chung WY
PLoS One; 2015; 10(4):e0122764. PubMed ID: 25859665
[TBL] [Abstract][Full Text] [Related]
52. Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1.
Takatsuna H; Asagiri M; Kubota T; Oka K; Osada T; Sugiyama C; Saito H; Aoki K; Ohya K; Takayanagi H; Umezawa K
J Bone Miner Res; 2005 Apr; 20(4):653-62. PubMed ID: 15765185
[TBL] [Abstract][Full Text] [Related]
53. Schisantherin A suppresses osteoclast formation and wear particle-induced osteolysis via modulating RANKL signaling pathways.
He Y; Zhang Q; Shen Y; Chen X; Zhou F; Peng D
Biochem Biophys Res Commun; 2014 Jul; 449(3):344-50. PubMed ID: 24845381
[TBL] [Abstract][Full Text] [Related]
54. Cathepsin G enhances mammary tumor-induced osteolysis by generating soluble receptor activator of nuclear factor-kappaB ligand.
Wilson TJ; Nannuru KC; Futakuchi M; Sadanandam A; Singh RK
Cancer Res; 2008 Jul; 68(14):5803-11. PubMed ID: 18632634
[TBL] [Abstract][Full Text] [Related]
55. Puerarin inhibits titanium particle-induced osteolysis and RANKL-induced osteoclastogenesis via suppression of the NF-κB signaling pathway.
Tang W; Xiao L; Ge G; Zhong M; Zhu J; Qin J; Feng C; Zhang W; Bai J; Zhu X; Wei M; Geng D; Wang Z
J Cell Mol Med; 2020 Oct; 24(20):11972-11983. PubMed ID: 32896108
[TBL] [Abstract][Full Text] [Related]
56. Inhibition of RIPK1/RIPK3 ameliorates osteoclastogenesis through regulating NLRP3-dependent NF-κB and MAPKs signaling pathways.
Liang S; Nian Z; Shi K
Biochem Biophys Res Commun; 2020 Jun; 526(4):1028-1035. PubMed ID: 32321638
[TBL] [Abstract][Full Text] [Related]
57. IL-11 produced by breast cancer cells augments osteoclastogenesis by sustaining the pool of osteoclast progenitor cells.
McCoy EM; Hong H; Pruitt HC; Feng X
BMC Cancer; 2013 Jan; 13():16. PubMed ID: 23311882
[TBL] [Abstract][Full Text] [Related]
58. Licorice isoliquiritigenin suppresses RANKL-induced osteoclastogenesis in vitro and prevents inflammatory bone loss in vivo.
Zhu L; Wei H; Wu Y; Yang S; Xiao L; Zhang J; Peng B
Int J Biochem Cell Biol; 2012 Jul; 44(7):1139-52. PubMed ID: 22521613
[TBL] [Abstract][Full Text] [Related]
59. The protective effect of WKYMVm peptide on inflammatory osteolysis through regulating NF-κB and CD9/gp130/STAT3 signalling pathway.
Hu J; Li X; Chen Y; Han X; Li L; Yang Z; Duan L; Lu H; He Q
J Cell Mol Med; 2020 Jan; 24(2):1893-1905. PubMed ID: 31837208
[TBL] [Abstract][Full Text] [Related]
60. Sophorae Flos extract inhibits RANKL-induced osteoclast differentiation by suppressing the NF-κB/NFATc1 pathway in mouse bone marrow cells.
Kim JM; Lee JH; Lee GS; Noh EM; Song HK; Gu DR; Kim SC; Lee SH; Kwon KB; Lee YR
BMC Complement Altern Med; 2017 Mar; 17(1):164. PubMed ID: 28335757
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
